Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adults ( male or female) 18-60 years of age~* Acute, symptomatic, non-severe (minimum Hb.5 gm/dL) VL proven by parasitological examination of splenic or bone marrow aspirate.~* History of fever.~* Living within reachable distance of the trial site to enable attendance for follow-up visits~* Written informed consent to participate~* Proven HIV negative status~* Women of child-bearing potential who are using an assured method of contraception~Exclusion Criteria:~* Signs/symptoms indicative of severe VL ( Hb.\< 5gm/dl, evidence of cardiac failure, etc)~* Patients who have received anti-leishmanial or anti-fungal treatment within the last 45 days~* Patients who have received any investigational (unlicensed) drugs within the last 6 months~* Severe malnutrition BMI\<15 in adults, weight for height less than 60% in children.~* Chronic underlying disease such as severe cardiac, renal, or hepatic impairment.~* Renal function tests (serum creatinine) outside the normal range~* Liver function tests (transaminases) more than three times the upper limit of the normal range at study entry~* Jaundice (bilirubin \>2.0mg/dL)~* Known hepatitis B or C positive~* Platelet count less than 40,000/mm3~* Prothrombin time 5 seconds or greater than normal range~* TotalWBC \< 1,000/mm3~* Known alcohol or other drug abuse~* HIV positive status~* Pregnancy and/or lactation~* Females having unprotected sexual intercourse, or using a non-assured method of contraception (e.g. condom)~* Concomitant chronic drug treatment eg for diabetes, hypertension, TB, HIV etc~* Concomitant drug usage for acute infection, eg malaria, pneumonia etc within the last 7 days~* Any other condition which may invalidate the trial~* Known hypersensitivity to AmBisome, Paromomycin, amphotericin B and/or Miltefosine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).